-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

695 First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO StudyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. CLL: Therapy, excluding Transplantation: Advances in CLL Using Novel Combination Therapy
Hematology Disease Topics & Pathways:
Leukemia, Adult, apoptosis, Diseases, Biological, Therapies, CLL, Non-Biological, chemotherapy, Biological Processes, enzyme inhibitors, Study Population, immunotherapy, Lymphoid Malignancies
Monday, December 3, 2018: 11:30 AM
Ballroom 20A (San Diego Convention Center)

Arnon P. Kater, MD1, Peter Hillmen, MB ChB, PhD, FRCP, FRCPath2, Barbara Eichhorst3*, Anton W Langerak, PhD4*, Thomas J. Kipps, MD, PhD5, Carolyn Owen, MD, FRCPC6, Michelle Boyer7*, Kathryn Humphrey7*, Elizabeth A Punnoose8*, Jue Wang8*, Brenda Chyla9*, Maria E. Verdugo9, Jenny Wu8*, Yanwen Jiang8*, Mehrdad Mobasher, MD, MPH8 and John F. Seymour, MBBS, PhD10

1University of Amsterdam, Department of Hematology, Hovon CLL working group, The Netherlands, Amsterdam, Netherlands
2St. James’s University Hospital, Leeds, United Kingdom
3Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany
4Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, Netherlands
5Moores Cancer Center, University of California School, San Diego, CA
6University of Calgary, Calgary, AB, Canada
7Roche Products Limited, Welwyn Garden City, United Kingdom
8Genentech Inc, South San Francisco, CA
9AbbVie, Inc., North Chicago, IL
10Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Introduction

Although CLL minimal residual disease (MRD) status is used in contemporary clinical trials aimed at maximizing response or determining treatment duration, its role as a predictive factor for PFS has only been established following chemoimmunotherapy. In contrast, whether MRD is a valuable tool for treatment choice in the era of novel targeted agents for CLL is unknown. Unlike kinase inhibitors, the BCL2 inhibitor venetoclax does result in undetectable MRD (uMRD). MURANO demonstrated significant PFS benefit for venetoclax + rituximab (VenR) given for a fixed duration vs bendamustine + rituximab (BR) in relapsed/refractory (R/R) CLL. Here we present analysis of peripheral blood (PB) MRD kinetics in relation to PFS in MURANO with long follow up, when all pts have completed therapy.

Methods

Pts were randomized to VenR (Ven 400mg/d for 2 yrs + R for first 6 mo) or BR (6 mo). Response was assessed clinically using complete blood count and physical exam at follow-up visits. PB MRD was analysed centrally by ASO-PCR and/or flow cytometry at Cycle 4, end of combination therapy (EOCT; mo 9) and every 3 mo thereafter until 3 yrs, then every 6 mo. As strong concordance between PB and bone marrow (BM) MRD with VenR was previously shown (Hillmen et al. ASCO 2018), we focus on PB MRD. Pts were categorized into uMRD (<1 CLL cell per 10,000 leukocytes [<10–4]), intermediate (int)-MRD+ (≥10–4 – <10–2), and high-MRD+ (≥10–2) status. Results are reported for the intention-to-treat (ITT) population.

Results

As of May 8 2018, median follow-up was 36.0 mo. VenR pts achieved high PB uMRD rates at EOCT (62% vs 13% for BR). The same pattern was observed through mo 24, when Ven single-agent treatment was scheduled to cease: 48% uMRD in VenR vs 2% in BR, and 16% int-MRD+ in VenR vs 7% in BR (Table 1). By then, 18% pts in the VenR arm had progressed/died/withdrew from study vs 66% in BR. Consistently high uMRD rates were observed in all VenR subgroups, including pts with high-risk cytogenetics and molecular factors: del(17p) and/or TP53 mutated: 57% at EOCT and 36% at mo 24; IGHV unmutated: 61% at EOCT and 51% at mo 24.

Landmark analysis of PFS by MRD status in PB at the EOCT response visit showed that, regardless of treatment arm, uMRD status was associated with longer PFS. Within MRD+ pts, the int-MRD+ group had improved PFS over high-MRD+ pts (Fig 1). Due to the very low rate of uMRD in the BR arm, all further analyses were performed in VenR pts; PFS curves overlapped for pts with uMRD, regardless of whether in CR or PR by investigator assessment, while inferior PFS for MRD+ PR/nPR pts becomes manifest from mo 18 after EOCT (Fig 2). MRD+ pts in CR (all int-MRD+) did as well as uMRD, but numbers are very small.

130 pts in VenR arm completed 2 yrs Ven treatment without PD; among them: 83 (64%) were uMRD, 23 (18%) were int-MRD+, 14 (10%) were high-MRD+ and 10 (8%) had missing data at mo 24. With 9.9 mo median follow-up from Ven completion, amongst uMRD pts at mo 24, the majority remained uMRD (57/83, 69%) and 26/83 (31%) converted to confirmed MRD+ (2 serial assay positive). Conversions were mainly to int-MRD+ (21/26, 81%), all of whom remain PFS event-free; 19% (5/26) converted to high-MRD+, 2 had PD per iwCLL criteria (Fig 3). Of pts converting from uMRD to MRD+ after cessation of Ven at mo 24, 40% (10/25) carried del(17p) and/or TP53 mutation, vs 23% (12/53) among those who did not convert. Of int-MRD+ pts at mo 24, 9/23 (39%) became high-MRD+ (2 had PD); there was 1 PD among the remaining 14. PD was seen in 11/14 (79%) of pts who were high-MRD+ at mo 24.

Conclusion

The higher PB uMRD rate observed at EOCT in the VenR arm vs BR arm was maintained at completion of Ven treatment, including in high-risk subgroups, consistent with maintained PFS benefit seen with longer follow up. VenR pts who achieved uMRD or int-MRD+ had durable PFS. MRD status powerfully identified distinct outcomes for pts with PR/nPR; longer follow-up is needed to determine the impact of MRD status among CR/CRi. In the first yr post-completion of fixed-duration VenR treatment, majority of uMRD pts remained uMRD; reemergence of MRD+, mainly at int levels, is seen in a minority of pts, and has shown a low rate of progression to clinical PD to date. These data are the first to demonstrate the value of PB MRD as a predictive marker of clinical outcome for the fixed-duration chemotherapy-free regimen, VenR. Our data corroborate that uMRD and int-MRD+ rate is a meaningful endpoint and desirable goal of CLL therapies, including targeted agents.

Disclosures: Kater: Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Hillmen: Celgene: Research Funding; Pharmacyclics: Research Funding; Novartis: Research Funding; Alexion Pharmaceuticals, Inc: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Research Funding; Gilead Sciences, Inc.: Honoraria, Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta: Membership on an entity's Board of Directors or advisory committees. Eichhorst: AbbVie, Celgene, Gilead, Janssen, Mundipharma, Novartis, Roche: Honoraria, Other: Travel support, Research Funding. Langerak: Gilead: Research Funding; AbbVie: Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; InVivoScribe Technologies: Patents & Royalties. Kipps: Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Verastem: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Genentech Inc: Consultancy, Research Funding; Verastem: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Gilead: Consultancy, Honoraria, Research Funding. Owen: Janssen: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; AbbVie: Research Funding; Merck: Honoraria; Pharmacyclics: Research Funding; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding; Teva: Honoraria; Celgene: Research Funding. Boyer: F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Humphrey: F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Punnoose: Genentech Inc: Employment; Roche: Equity Ownership. Wang: Genentech Inc: Employment; F. Hoffmann-La Roche Ltd: Equity Ownership. Chyla: AbbVie, Inc: Employment, Equity Ownership. Verdugo: AbbVie, Inc: Employment, Equity Ownership. Wu: Genentech Inc: Employment. Jiang: Genentech Inc: Employment, Equity Ownership. Mobasher: F. Hoffmann-La Roche Ltd: Employment, Equity Ownership, Other: Ownership interests non-PLC; Genentech Inc: Employment. Seymour: AbbVie: Consultancy, Honoraria, Research Funding; Genentech Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Research Funding; Celgene: Consultancy.

*signifies non-member of ASH